30 results found.

Leukemia, Myelogenous, Chronic Clinical Trial using Nilotinib

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.
Nilotinib

Chronic Myelogenous Leukemia Clinical Trial using nilotinib; imatinib

Novartis - Recruiting 16 years or older.
- A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib.
nilotinib; imatinib

Chronic Myelogenous Leukemia Clinical Trial using Chart Review

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial.
Chart Review

Leukemia Clinical Trial using Dasatinib; Decitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357).
Dasatinib; Decitabine

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Ac Clinical Trial using supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 4 years to 21 years.
- A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Children's Oncology Group - Recruiting N/A or older.
- Umbrella Long-Term Follow-Up Protocol.
survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute L Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History.

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Chronic Myelogenous Leukemia in Chronic Phase Clinical Trial using nilotinib

Novartis - Recruiting 18 years or older.
- A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP).
nilotinib

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias.
temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chr Clinical Trial using total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years.
- A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using pentostatin; therapeutic allogeneic lymphocytes; mycophenolate mofetil; cyclosporine

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multi-Center Trial.
pentostatin; therapeutic allogeneic lymphocytes; mycophenolate mofetil; cyclosporine

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML.
WT1-sensitized T cells; aldesleukin; laboratory biomarker analysis

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Myelogenous Leukemia, Chronic, Chronic Phase Clinical Trial using dasatinib

Kanto CML Study Group - Recruiting 15 years or older.
- Phase?Clinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS.
dasatinib

Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloprolife Clinical Trial using ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years.
- Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or Myelogenous Clinical Trial

Kanto CML Study Group - Recruiting 20 Months or older.
- Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.